ABT199/venetoclax synergism with thiotepa enhances cytotoxicity of chemo drugs in AML cells

A new research paper was published in Oncotarget’s Volume 15 on March 14, 2024, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.”

Celltrion’s SteQeyma gets EC approval for inflammatory diseases

Clinical data confirmed that SteQeyma is highly similar to Stelara, without any significant differences in efficacy and safety. Credit: pedro7merino/Shutterstock. The European Commission (EC) has

August 26, 2024

Lantheus hands Perspective Therapeutics $28M upfront to expand its radiopharma options

Radiopharma company Lantheus is looking to build up its portfolio through a collaboration with Perspective Therapeutics. By handing Perspective $28 million upfront, Lantheus has the

January 10, 2024

SyntheticGestalt, Enamine to develop AI drug discovery models

Share this article SyntheticGestalt will create a pre-trained artificial intelligence (AI) model to develop synthesisable drug-like candidates. Credit: metamorworks/Shutterstock.com. SyntheticGestalt and Enamine have announced a

January 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.